Form: 10-Q

Quarterly report pursuant to Section 13 or 15(d)

April 26, 2023

Documents

false2023Q10001659166December 31http://fasb.org/us-gaap/2022#AccountingStandardsUpdate202006MemberP3Y10000016591662023-01-012023-03-3100016591662023-04-21xbrli:shares00016591662023-03-31iso4217:USD00016591662022-12-31iso4217:USDxbrli:shares0001659166us-gaap:ProductMember2023-01-012023-03-310001659166us-gaap:ProductMember2022-01-012022-04-010001659166us-gaap:ServiceMember2023-01-012023-03-310001659166us-gaap:ServiceMember2022-01-012022-04-0100016591662022-01-012022-04-010001659166us-gaap:CommonStockMember2022-12-310001659166us-gaap:AdditionalPaidInCapitalMember2022-12-310001659166us-gaap:TreasuryStockMember2022-12-310001659166us-gaap:RetainedEarningsMember2022-12-310001659166us-gaap:AccumulatedOtherComprehensiveIncomeMember2022-12-310001659166us-gaap:NoncontrollingInterestMember2022-12-310001659166us-gaap:RetainedEarningsMember2023-01-012023-03-310001659166us-gaap:NoncontrollingInterestMember2023-01-012023-03-310001659166us-gaap:AccumulatedOtherComprehensiveIncomeMember2023-01-012023-03-310001659166us-gaap:CommonStockMember2023-01-012023-03-310001659166us-gaap:AdditionalPaidInCapitalMember2023-01-012023-03-310001659166us-gaap:CommonStockMember2023-03-310001659166us-gaap:AdditionalPaidInCapitalMember2023-03-310001659166us-gaap:TreasuryStockMember2023-03-310001659166us-gaap:RetainedEarningsMember2023-03-310001659166us-gaap:AccumulatedOtherComprehensiveIncomeMember2023-03-310001659166us-gaap:NoncontrollingInterestMember2023-03-310001659166us-gaap:CommonStockMember2021-12-310001659166us-gaap:AdditionalPaidInCapitalMember2021-12-310001659166us-gaap:TreasuryStockMember2021-12-310001659166us-gaap:RetainedEarningsMember2021-12-310001659166us-gaap:AccumulatedOtherComprehensiveIncomeMember2021-12-310001659166us-gaap:NoncontrollingInterestMember2021-12-3100016591662021-01-012021-12-310001659166srt:CumulativeEffectPeriodOfAdoptionAdjustmentMemberus-gaap:AdditionalPaidInCapitalMember2021-12-310001659166us-gaap:RetainedEarningsMembersrt:CumulativeEffectPeriodOfAdoptionAdjustmentMember2021-12-310001659166srt:CumulativeEffectPeriodOfAdoptionAdjustmentMemberus-gaap:NoncontrollingInterestMember2021-12-310001659166srt:CumulativeEffectPeriodOfAdoptionAdjustedBalanceMember2021-12-310001659166srt:CumulativeEffectPeriodOfAdoptionAdjustedBalanceMemberus-gaap:AdditionalPaidInCapitalMember2021-12-310001659166us-gaap:TreasuryStockMembersrt:CumulativeEffectPeriodOfAdoptionAdjustedBalanceMember2021-12-310001659166us-gaap:RetainedEarningsMembersrt:CumulativeEffectPeriodOfAdoptionAdjustedBalanceMember2021-12-310001659166srt:CumulativeEffectPeriodOfAdoptionAdjustedBalanceMemberus-gaap:AccumulatedOtherComprehensiveIncomeMember2021-12-310001659166us-gaap:NoncontrollingInterestMembersrt:CumulativeEffectPeriodOfAdoptionAdjustedBalanceMember2021-12-310001659166us-gaap:RetainedEarningsMember2022-01-012022-04-010001659166us-gaap:NoncontrollingInterestMember2022-01-012022-04-010001659166us-gaap:AccumulatedOtherComprehensiveIncomeMember2022-01-012022-04-010001659166us-gaap:CommonStockMember2022-01-012022-04-010001659166us-gaap:AdditionalPaidInCapitalMember2022-01-012022-04-010001659166us-gaap:TreasuryStockMember2022-01-012022-04-010001659166us-gaap:CommonStockMember2022-04-010001659166us-gaap:AdditionalPaidInCapitalMember2022-04-010001659166us-gaap:TreasuryStockMember2022-04-010001659166us-gaap:RetainedEarningsMember2022-04-010001659166us-gaap:AccumulatedOtherComprehensiveIncomeMember2022-04-010001659166us-gaap:NoncontrollingInterestMember2022-04-010001659166ftv:A0875SeniorConvertibleNotesDue2022Memberus-gaap:ConvertibleDebtMember2023-03-31xbrli:pure00016591662021-12-3100016591662022-04-01ftv:country0001659166ftv:YenTermLoanMember2022-07-01iso4217:JPY0001659166ftv:EuroTermLoanMember2022-07-01iso4217:EUR0001659166us-gaap:AccumulatedTranslationAdjustmentMember2022-12-310001659166us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember2022-12-310001659166us-gaap:AccumulatedTranslationAdjustmentMember2023-01-012023-03-310001659166us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember2023-01-012023-03-310001659166us-gaap:AccumulatedTranslationAdjustmentMember2023-03-310001659166us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember2023-03-310001659166us-gaap:AccumulatedTranslationAdjustmentMember2021-12-310001659166us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember2021-12-310001659166us-gaap:AccumulatedTranslationAdjustmentMember2022-01-012022-04-010001659166us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember2022-01-012022-04-010001659166us-gaap:AccumulatedTranslationAdjustmentMember2022-04-010001659166us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember2022-04-010001659166srt:MinimumMember2023-03-310001659166srt:MaximumMember2023-03-310001659166ftv:SeniorConvertibleNotesDue2022Memberus-gaap:ConvertibleDebtMember2019-02-222019-02-220001659166ftv:SeniorConvertibleNotesDue2022Memberus-gaap:ConvertibleDebtMember2023-03-310001659166ftv:EuroTermLoanMemberus-gaap:ConvertibleDebtMember2019-02-220001659166ftv:SeniorConvertibleNotesDue2022Memberus-gaap:ConvertibleDebtMember2022-02-152022-02-150001659166ftv:IntelligentOperatingSolutionsMember2022-12-310001659166ftv:PrecisionTechnologiesMember2022-12-310001659166ftv:AdvancedHealthcareSolutionsMember2022-12-310001659166ftv:IntelligentOperatingSolutionsMember2023-01-012023-03-310001659166ftv:PrecisionTechnologiesMember2023-01-012023-03-310001659166ftv:AdvancedHealthcareSolutionsMember2023-01-012023-03-310001659166ftv:IntelligentOperatingSolutionsMember2023-03-310001659166ftv:PrecisionTechnologiesMember2023-03-310001659166ftv:AdvancedHealthcareSolutionsMember2023-03-310001659166us-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMember2023-03-310001659166us-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel2Member2023-03-310001659166us-gaap:FairValueInputsLevel3Memberus-gaap:FairValueMeasurementsRecurringMember2023-03-310001659166us-gaap:FairValueMeasurementsRecurringMember2023-03-310001659166us-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMember2022-12-310001659166us-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel2Member2022-12-310001659166us-gaap:FairValueInputsLevel3Memberus-gaap:FairValueMeasurementsRecurringMember2022-12-310001659166us-gaap:FairValueMeasurementsRecurringMember2022-12-310001659166us-gaap:FairValueInputsLevel1Member2023-03-310001659166us-gaap:FairValueInputsLevel1Member2022-12-310001659166us-gaap:CommercialPaperMemberftv:USDollarDenominatedCommercialPaperMember2023-03-310001659166us-gaap:CommercialPaperMemberftv:USDollarDenominatedCommercialPaperMember2022-12-310001659166us-gaap:SecuredDebtMemberftv:DelayedDrawTermLoanDue2022Member2023-03-310001659166us-gaap:SecuredDebtMemberftv:DelayedDrawTermLoanDue2022Member2022-12-310001659166ftv:EuroTermLoanDueJune2025Memberus-gaap:SecuredDebtMember2023-03-310001659166ftv:EuroTermLoanDueJune2025Memberus-gaap:SecuredDebtMember2022-12-310001659166us-gaap:SecuredDebtMemberftv:YenTermLoanDueJune2025Member2023-03-310001659166us-gaap:SecuredDebtMemberftv:YenTermLoanDueJune2025Member2022-12-310001659166ftv:SeniorUnsecuredNotesdue2026Memberus-gaap:SeniorNotesMember2023-03-310001659166ftv:SeniorUnsecuredNotesdue2026Memberus-gaap:SeniorNotesMember2022-12-310001659166ftv:SeniorUnsecuredNotesdue2046Memberus-gaap:SeniorNotesMember2023-03-310001659166ftv:SeniorUnsecuredNotesdue2046Memberus-gaap:SeniorNotesMember2022-12-310001659166srt:MaximumMemberus-gaap:CommercialPaperMemberftv:USDollarDenominatedCommercialPaperMember2023-01-012023-03-310001659166ftv:EuroDenominatedCommercialPaperMembersrt:MaximumMemberus-gaap:CommercialPaperMember2023-01-012023-03-310001659166us-gaap:CommercialPaperMemberftv:USDollarDenominatedCommercialPaperMember2023-01-012023-03-310001659166us-gaap:RevolvingCreditFacilityMember2023-01-012023-03-310001659166us-gaap:RevolvingCreditFacilityMember2023-03-310001659166us-gaap:OperatingSegmentsMemberftv:IntelligentOperatingSolutionsMember2023-03-310001659166us-gaap:OperatingSegmentsMemberftv:PrecisionTechnologiesMember2023-03-310001659166us-gaap:OperatingSegmentsMemberftv:AdvancedHealthcareSolutionsMember2023-03-310001659166ftv:PeriodOneMember2023-04-012023-03-3100016591662023-04-01ftv:PeriodTwoMember2023-03-310001659166ftv:PeriodThreeMember2023-04-012023-03-310001659166us-gaap:OperatingSegmentsMemberus-gaap:ProductMemberftv:IntelligentOperatingSolutionsMember2023-01-012023-03-310001659166us-gaap:OperatingSegmentsMemberus-gaap:ProductMemberftv:PrecisionTechnologiesMember2023-01-012023-03-310001659166us-gaap:OperatingSegmentsMemberftv:AdvancedHealthcareSolutionsMemberus-gaap:ProductMember2023-01-012023-03-310001659166us-gaap:OperatingSegmentsMemberus-gaap:ServiceMemberftv:IntelligentOperatingSolutionsMember2023-01-012023-03-310001659166us-gaap:OperatingSegmentsMemberftv:PrecisionTechnologiesMemberus-gaap:ServiceMember2023-01-012023-03-310001659166us-gaap:OperatingSegmentsMemberftv:AdvancedHealthcareSolutionsMemberus-gaap:ServiceMember2023-01-012023-03-310001659166us-gaap:OperatingSegmentsMemberftv:IntelligentOperatingSolutionsMember2023-01-012023-03-310001659166us-gaap:OperatingSegmentsMemberftv:PrecisionTechnologiesMember2023-01-012023-03-310001659166us-gaap:OperatingSegmentsMemberftv:AdvancedHealthcareSolutionsMember2023-01-012023-03-310001659166country:US2023-01-012023-03-310001659166country:USus-gaap:OperatingSegmentsMemberftv:IntelligentOperatingSolutionsMember2023-01-012023-03-310001659166country:USus-gaap:OperatingSegmentsMemberftv:PrecisionTechnologiesMember2023-01-012023-03-310001659166country:USus-gaap:OperatingSegmentsMemberftv:AdvancedHealthcareSolutionsMember2023-01-012023-03-310001659166country:CN2023-01-012023-03-310001659166us-gaap:OperatingSegmentsMembercountry:CNftv:IntelligentOperatingSolutionsMember2023-01-012023-03-310001659166us-gaap:OperatingSegmentsMembercountry:CNftv:PrecisionTechnologiesMember2023-01-012023-03-310001659166us-gaap:OperatingSegmentsMembercountry:CNftv:AdvancedHealthcareSolutionsMember2023-01-012023-03-310001659166ftv:CountriesExcludingUnitedStatesandChinaMember2023-01-012023-03-310001659166us-gaap:OperatingSegmentsMemberftv:CountriesExcludingUnitedStatesandChinaMemberftv:IntelligentOperatingSolutionsMember2023-01-012023-03-310001659166us-gaap:OperatingSegmentsMemberftv:CountriesExcludingUnitedStatesandChinaMemberftv:PrecisionTechnologiesMember2023-01-012023-03-310001659166us-gaap:OperatingSegmentsMemberftv:CountriesExcludingUnitedStatesandChinaMemberftv:AdvancedHealthcareSolutionsMember2023-01-012023-03-310001659166ftv:HealthcareMember2023-01-012023-03-310001659166us-gaap:OperatingSegmentsMemberftv:HealthcareMemberftv:IntelligentOperatingSolutionsMember2023-01-012023-03-310001659166us-gaap:OperatingSegmentsMemberftv:PrecisionTechnologiesMemberftv:HealthcareMember2023-01-012023-03-310001659166us-gaap:OperatingSegmentsMemberftv:AdvancedHealthcareSolutionsMemberftv:HealthcareMember2023-01-012023-03-310001659166ftv:IndustrialManufacturingMember2023-01-012023-03-310001659166us-gaap:OperatingSegmentsMemberftv:IndustrialManufacturingMemberftv:IntelligentOperatingSolutionsMember2023-01-012023-03-310001659166us-gaap:OperatingSegmentsMemberftv:PrecisionTechnologiesMemberftv:IndustrialManufacturingMember2023-01-012023-03-310001659166us-gaap:OperatingSegmentsMemberftv:AdvancedHealthcareSolutionsMemberftv:IndustrialManufacturingMember2023-01-012023-03-310001659166ftv:UtilitiesPowerMember2023-01-012023-03-310001659166us-gaap:OperatingSegmentsMemberftv:UtilitiesPowerMemberftv:IntelligentOperatingSolutionsMember2023-01-012023-03-310001659166us-gaap:OperatingSegmentsMemberftv:PrecisionTechnologiesMemberftv:UtilitiesPowerMember2023-01-012023-03-310001659166us-gaap:OperatingSegmentsMemberftv:AdvancedHealthcareSolutionsMemberftv:UtilitiesPowerMember2023-01-012023-03-310001659166us-gaap:GovernmentMember2023-01-012023-03-310001659166us-gaap:GovernmentMemberus-gaap:OperatingSegmentsMemberftv:IntelligentOperatingSolutionsMember2023-01-012023-03-310001659166us-gaap:GovernmentMemberus-gaap:OperatingSegmentsMemberftv:PrecisionTechnologiesMember2023-01-012023-03-310001659166us-gaap:GovernmentMemberus-gaap:OperatingSegmentsMemberftv:AdvancedHealthcareSolutionsMember2023-01-012023-03-310001659166ftv:CommunicationElectronicsAndSemiconductorMember2023-01-012023-03-310001659166ftv:CommunicationElectronicsAndSemiconductorMemberus-gaap:OperatingSegmentsMemberftv:IntelligentOperatingSolutionsMember2023-01-012023-03-310001659166ftv:CommunicationElectronicsAndSemiconductorMemberus-gaap:OperatingSegmentsMemberftv:PrecisionTechnologiesMember2023-01-012023-03-310001659166ftv:CommunicationElectronicsAndSemiconductorMemberus-gaap:OperatingSegmentsMemberftv:AdvancedHealthcareSolutionsMember2023-01-012023-03-310001659166ftv:AerospaceAndDefenseMember2023-01-012023-03-310001659166ftv:AerospaceAndDefenseMemberus-gaap:OperatingSegmentsMemberftv:IntelligentOperatingSolutionsMember2023-01-012023-03-310001659166ftv:AerospaceAndDefenseMemberus-gaap:OperatingSegmentsMemberftv:PrecisionTechnologiesMember2023-01-012023-03-310001659166ftv:AerospaceAndDefenseMemberus-gaap:OperatingSegmentsMemberftv:AdvancedHealthcareSolutionsMember2023-01-012023-03-310001659166us-gaap:OilAndGasMember2023-01-012023-03-310001659166us-gaap:OperatingSegmentsMemberus-gaap:OilAndGasMemberftv:IntelligentOperatingSolutionsMember2023-01-012023-03-310001659166us-gaap:OperatingSegmentsMemberftv:PrecisionTechnologiesMemberus-gaap:OilAndGasMember2023-01-012023-03-310001659166us-gaap:OperatingSegmentsMemberftv:AdvancedHealthcareSolutionsMemberus-gaap:OilAndGasMember2023-01-012023-03-310001659166ftv:RetailAndConsumerMember2023-01-012023-03-310001659166ftv:RetailAndConsumerMemberus-gaap:OperatingSegmentsMemberftv:IntelligentOperatingSolutionsMember2023-01-012023-03-310001659166ftv:RetailAndConsumerMemberus-gaap:OperatingSegmentsMemberftv:PrecisionTechnologiesMember2023-01-012023-03-310001659166ftv:RetailAndConsumerMemberus-gaap:OperatingSegmentsMemberftv:AdvancedHealthcareSolutionsMember2023-01-012023-03-310001659166ftv:OtherDirectEndMarketsMember2023-01-012023-03-310001659166us-gaap:OperatingSegmentsMemberftv:OtherDirectEndMarketsMemberftv:IntelligentOperatingSolutionsMember2023-01-012023-03-310001659166us-gaap:OperatingSegmentsMemberftv:PrecisionTechnologiesMemberftv:OtherDirectEndMarketsMember2023-01-012023-03-310001659166us-gaap:OperatingSegmentsMemberftv:AdvancedHealthcareSolutionsMemberftv:OtherDirectEndMarketsMember2023-01-012023-03-310001659166ftv:DirectEndMarketsMember2023-01-012023-03-310001659166us-gaap:OperatingSegmentsMemberftv:DirectEndMarketsMemberftv:IntelligentOperatingSolutionsMember2023-01-012023-03-310001659166us-gaap:OperatingSegmentsMemberftv:PrecisionTechnologiesMemberftv:DirectEndMarketsMember2023-01-012023-03-310001659166us-gaap:OperatingSegmentsMemberftv:AdvancedHealthcareSolutionsMemberftv:DirectEndMarketsMember2023-01-012023-03-310001659166ftv:OtherDistributorsMember2023-01-012023-03-310001659166us-gaap:OperatingSegmentsMemberftv:OtherDistributorsMemberftv:IntelligentOperatingSolutionsMember2023-01-012023-03-310001659166us-gaap:OperatingSegmentsMemberftv:OtherDistributorsMemberftv:PrecisionTechnologiesMember2023-01-012023-03-310001659166us-gaap:OperatingSegmentsMemberftv:AdvancedHealthcareSolutionsMemberftv:OtherDistributorsMember2023-01-012023-03-310001659166us-gaap:OperatingSegmentsMemberus-gaap:ProductMemberftv:IntelligentOperatingSolutionsMember2022-01-012022-04-010001659166us-gaap:OperatingSegmentsMemberus-gaap:ProductMemberftv:PrecisionTechnologiesMember2022-01-012022-04-010001659166us-gaap:OperatingSegmentsMemberftv:AdvancedHealthcareSolutionsMemberus-gaap:ProductMember2022-01-012022-04-010001659166us-gaap:OperatingSegmentsMemberus-gaap:ServiceMemberftv:IntelligentOperatingSolutionsMember2022-01-012022-04-010001659166us-gaap:OperatingSegmentsMemberftv:PrecisionTechnologiesMemberus-gaap:ServiceMember2022-01-012022-04-010001659166us-gaap:OperatingSegmentsMemberftv:AdvancedHealthcareSolutionsMemberus-gaap:ServiceMember2022-01-012022-04-010001659166us-gaap:OperatingSegmentsMemberftv:IntelligentOperatingSolutionsMember2022-01-012022-04-010001659166us-gaap:OperatingSegmentsMemberftv:PrecisionTechnologiesMember2022-01-012022-04-010001659166us-gaap:OperatingSegmentsMemberftv:AdvancedHealthcareSolutionsMember2022-01-012022-04-010001659166country:US2022-01-012022-04-010001659166country:USus-gaap:OperatingSegmentsMemberftv:IntelligentOperatingSolutionsMember2022-01-012022-04-010001659166country:USus-gaap:OperatingSegmentsMemberftv:PrecisionTechnologiesMember2022-01-012022-04-010001659166country:USus-gaap:OperatingSegmentsMemberftv:AdvancedHealthcareSolutionsMember2022-01-012022-04-010001659166country:CN2022-01-012022-04-010001659166us-gaap:OperatingSegmentsMembercountry:CNftv:IntelligentOperatingSolutionsMember2022-01-012022-04-010001659166us-gaap:OperatingSegmentsMembercountry:CNftv:PrecisionTechnologiesMember2022-01-012022-04-010001659166us-gaap:OperatingSegmentsMembercountry:CNftv:AdvancedHealthcareSolutionsMember2022-01-012022-04-010001659166ftv:CountriesExcludingUnitedStatesandChinaMember2022-01-012022-04-010001659166us-gaap:OperatingSegmentsMemberftv:CountriesExcludingUnitedStatesandChinaMemberftv:IntelligentOperatingSolutionsMember2022-01-012022-04-010001659166us-gaap:OperatingSegmentsMemberftv:CountriesExcludingUnitedStatesandChinaMemberftv:PrecisionTechnologiesMember2022-01-012022-04-010001659166us-gaap:OperatingSegmentsMemberftv:CountriesExcludingUnitedStatesandChinaMemberftv:AdvancedHealthcareSolutionsMember2022-01-012022-04-010001659166ftv:HealthcareMember2022-01-012022-04-010001659166us-gaap:OperatingSegmentsMemberftv:HealthcareMemberftv:IntelligentOperatingSolutionsMember2022-01-012022-04-010001659166us-gaap:OperatingSegmentsMemberftv:PrecisionTechnologiesMemberftv:HealthcareMember2022-01-012022-04-010001659166us-gaap:OperatingSegmentsMemberftv:AdvancedHealthcareSolutionsMemberftv:HealthcareMember2022-01-012022-04-010001659166ftv:IndustrialManufacturingMember2022-01-012022-04-010001659166us-gaap:OperatingSegmentsMemberftv:IndustrialManufacturingMemberftv:IntelligentOperatingSolutionsMember2022-01-012022-04-010001659166us-gaap:OperatingSegmentsMemberftv:PrecisionTechnologiesMemberftv:IndustrialManufacturingMember2022-01-012022-04-010001659166us-gaap:OperatingSegmentsMemberftv:AdvancedHealthcareSolutionsMemberftv:IndustrialManufacturingMember2022-01-012022-04-010001659166ftv:UtilitiesPowerMember2022-01-012022-04-010001659166us-gaap:OperatingSegmentsMemberftv:UtilitiesPowerMemberftv:IntelligentOperatingSolutionsMember2022-01-012022-04-010001659166us-gaap:OperatingSegmentsMemberftv:PrecisionTechnologiesMemberftv:UtilitiesPowerMember2022-01-012022-04-010001659166us-gaap:OperatingSegmentsMemberftv:AdvancedHealthcareSolutionsMemberftv:UtilitiesPowerMember2022-01-012022-04-010001659166us-gaap:GovernmentMember2022-01-012022-04-010001659166us-gaap:GovernmentMemberus-gaap:OperatingSegmentsMemberftv:IntelligentOperatingSolutionsMember2022-01-012022-04-010001659166us-gaap:GovernmentMemberus-gaap:OperatingSegmentsMemberftv:PrecisionTechnologiesMember2022-01-012022-04-010001659166us-gaap:GovernmentMemberus-gaap:OperatingSegmentsMemberftv:AdvancedHealthcareSolutionsMember2022-01-012022-04-010001659166ftv:CommunicationElectronicsAndSemiconductorMember2022-01-012022-04-010001659166ftv:CommunicationElectronicsAndSemiconductorMemberus-gaap:OperatingSegmentsMemberftv:IntelligentOperatingSolutionsMember2022-01-012022-04-010001659166ftv:CommunicationElectronicsAndSemiconductorMemberus-gaap:OperatingSegmentsMemberftv:PrecisionTechnologiesMember2022-01-012022-04-010001659166ftv:CommunicationElectronicsAndSemiconductorMemberus-gaap:OperatingSegmentsMemberftv:AdvancedHealthcareSolutionsMember2022-01-012022-04-010001659166ftv:AerospaceAndDefenseMember2022-01-012022-04-010001659166ftv:AerospaceAndDefenseMemberus-gaap:OperatingSegmentsMemberftv:IntelligentOperatingSolutionsMember2022-01-012022-04-010001659166ftv:AerospaceAndDefenseMemberus-gaap:OperatingSegmentsMemberftv:PrecisionTechnologiesMember2022-01-012022-04-010001659166ftv:AerospaceAndDefenseMemberus-gaap:OperatingSegmentsMemberftv:AdvancedHealthcareSolutionsMember2022-01-012022-04-010001659166us-gaap:OilAndGasMember2022-01-012022-04-010001659166us-gaap:OperatingSegmentsMemberus-gaap:OilAndGasMemberftv:IntelligentOperatingSolutionsMember2022-01-012022-04-010001659166us-gaap:OperatingSegmentsMemberftv:PrecisionTechnologiesMemberus-gaap:OilAndGasMember2022-01-012022-04-010001659166us-gaap:OperatingSegmentsMemberftv:AdvancedHealthcareSolutionsMemberus-gaap:OilAndGasMember2022-01-012022-04-010001659166ftv:RetailAndConsumerMember2022-01-012022-04-010001659166ftv:RetailAndConsumerMemberus-gaap:OperatingSegmentsMemberftv:IntelligentOperatingSolutionsMember2022-01-012022-04-010001659166ftv:RetailAndConsumerMemberus-gaap:OperatingSegmentsMemberftv:PrecisionTechnologiesMember2022-01-012022-04-010001659166ftv:RetailAndConsumerMemberus-gaap:OperatingSegmentsMemberftv:AdvancedHealthcareSolutionsMember2022-01-012022-04-010001659166ftv:OtherDirectEndMarketsMember2022-01-012022-04-010001659166us-gaap:OperatingSegmentsMemberftv:OtherDirectEndMarketsMemberftv:IntelligentOperatingSolutionsMember2022-01-012022-04-010001659166us-gaap:OperatingSegmentsMemberftv:PrecisionTechnologiesMemberftv:OtherDirectEndMarketsMember2022-01-012022-04-010001659166us-gaap:OperatingSegmentsMemberftv:AdvancedHealthcareSolutionsMemberftv:OtherDirectEndMarketsMember2022-01-012022-04-010001659166ftv:DirectEndMarketsMember2022-01-012022-04-010001659166us-gaap:OperatingSegmentsMemberftv:DirectEndMarketsMemberftv:IntelligentOperatingSolutionsMember2022-01-012022-04-010001659166us-gaap:OperatingSegmentsMemberftv:PrecisionTechnologiesMemberftv:DirectEndMarketsMember2022-01-012022-04-010001659166us-gaap:OperatingSegmentsMemberftv:AdvancedHealthcareSolutionsMemberftv:DirectEndMarketsMember2022-01-012022-04-010001659166ftv:OtherDistributorsMember2022-01-012022-04-010001659166us-gaap:OperatingSegmentsMemberftv:OtherDistributorsMemberftv:IntelligentOperatingSolutionsMember2022-01-012022-04-010001659166us-gaap:OperatingSegmentsMemberftv:OtherDistributorsMemberftv:PrecisionTechnologiesMember2022-01-012022-04-010001659166us-gaap:OperatingSegmentsMemberftv:AdvancedHealthcareSolutionsMemberftv:OtherDistributorsMember2022-01-012022-04-010001659166ftv:RestrictedStockUnitsRSUsandPerformanceShareUnitsPSUsMember2023-01-012023-03-310001659166ftv:RestrictedStockUnitsRSUsandPerformanceShareUnitsPSUsMember2022-01-012022-04-010001659166us-gaap:EmployeeStockOptionMember2023-01-012023-03-310001659166us-gaap:EmployeeStockOptionMember2022-01-012022-04-010001659166ftv:RestrictedStockUnitsRSUsandPerformanceShareUnitsPSUsMember2023-03-310001659166us-gaap:EmployeeStockOptionMember2023-03-3100016591662022-02-17ftv:segment0001659166us-gaap:OperatingSegmentsMember2023-01-012023-03-310001659166us-gaap:OperatingSegmentsMember2022-01-012022-04-010001659166us-gaap:CorporateNonSegmentMember2023-01-012023-03-310001659166us-gaap:CorporateNonSegmentMember2022-01-012022-04-01

 
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
________________________________________________
FORM 10-Q
 ________________________________________________
(Mark One)  
☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
For the quarterly period ended: March 31, 2023
Or
☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
For the transition period from            to            
Commission file number 1-37654
 ________________________________________________
Fortive Corporation
(Exact name of registrant as specified in its charter)
________________________________________________ 
 
Delaware   47-5654583
(State or other jurisdiction of
incorporation or organization)		   (I.R.S. employer
identification number)
6920 Seaway Blvd
Everett, WA 98203
(Address of principal executive offices) (Zip code)
Registrant’s telephone number, including area code: (425) 446-5000

Securities registered pursuant to Section 12(b) of the Act:
Title of each class Trading symbol Name of each exchange on which registered
Common stock, par value $0.01 per share FTV New York Stock Exchange

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 (the “Exchange Act”) during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes ☒ No ☐
Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). Yes ☒ No ☐
Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.








Large accelerated filer ☒ Accelerated filer ☐
Non-accelerated filer ☐ Smaller reporting company ☐
Emerging growth company ☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Indicate by check mark whether the registrant is a shell company (as defined by Rule 12b-2 of the Exchange Act). Yes ☐ No ☒
The number of shares of common stock outstanding at April 21, 2023 was 353,549,934.



FORTIVE CORPORATION
INDEX
FORM 10-Q
 
PART I - FINANCIAL INFORMATION Page
Item 1.
Item 2.
Item 3.
Item 4.
PART II - OTHER INFORMATION
Item 1A.
Item 2.
Item 6.

3
Table of Contents
PART I - FINANCIAL INFORMATION
ITEM 1. FINANCIAL STATEMENTS

FORTIVE CORPORATION AND SUBSIDIARIES
CONSOLIDATED CONDENSED BALANCE SHEETS
($ in millions, except share and per share amounts)
  As of
  March 31, 2023 December 31, 2022
  (unaudited)  
ASSETS
Current assets:
Cash and equivalents $ 672.8  $ 709.2 
Trade accounts receivable less allowance for doubtful accounts of $41.2 at March 31, 2023 and $43.9 at December 31, 2022
 940.7  958.5 
Inventories:
Finished goods 234.8  215.3 
Work in process 103.6  96.4 
Raw materials 231.8  225.0 
Inventories 570.2  536.7 
Prepaid expenses and other current assets 271.6  272.6 
Total current assets 2,455.3  2,477.0 
Property, plant and equipment, net of accumulated depreciation of $772.7 at March 31, 2023 and $754.5 at December 31, 2022
 425.6  421.9 
Other assets 470.0  455.8 
Goodwill 9,057.1  9,048.5 
Other intangible assets, net 3,396.8  3,487.4 
Total assets $ 15,804.8  $ 15,890.6 
LIABILITIES AND EQUITY
Current liabilities:
Current portion of long-term debt $ 999.8  $ 999.7 
Trade accounts payable 593.0  623.0 
Accrued expenses and other current liabilities 1,037.3  1,104.4 
Total current liabilities 2,630.1  2,727.1 
Other long-term liabilities 1,204.4  1,223.3 
Long-term debt 2,094.6  2,251.6 
Commitments and Contingencies (Note 8)
Equity:
Common stock: $0.01 par value, 2.0 billion shares authorized; 362.2 million issued and 353.5 million outstanding at March 31, 2023; 361.5 million issued and 352.9 million outstanding at December 31, 2022
 3.6  3.6 
Additional paid-in capital 3,730.5  3,706.3 
Treasury shares, at cost (442.9) (442.9)
Retained earnings 6,891.0  6,742.1 
Accumulated other comprehensive loss (312.3) (325.7)
Total Fortive stockholders’ equity 9,869.9  9,683.4 
Noncontrolling interests 5.8  5.2 
Total stockholders’ equity 9,875.7  9,688.6 
Total liabilities and equity $ 15,804.8  $ 15,890.6 
See the accompanying Notes to Consolidated Condensed Financial Statements.
4
Table of Contents
FORTIVE CORPORATION AND SUBSIDIARIES
CONSOLIDATED CONDENSED STATEMENTS OF EARNINGS
($ and shares in millions, except per share amounts)
(unaudited) 
  Three Months Ended
  March 31, 2023 April 1, 2022
Sales of products and software $ 1,236.6  $ 1,152.7 
Sales of services 224.1  223.8 
Total sales 1,460.7  1,376.5 
Cost of product and software sales (488.1) (465.1)
Cost of service sales (124.4) (119.4)
Total cost of sales (612.5) (584.5)
Gross profit 848.2  792.0 
Operating costs:
Selling, general and administrative expenses (507.7) (480.6)
Research and development expenses (100.1) (99.1)
Operating profit 240.4  212.3 
Non-operating income (expense), net:
Interest expense, net (32.1) (18.8)
Other non-operating expense, net (2.5) (2.7)
Earnings before income taxes 205.8  190.8 
Income taxes (32.2) (25.7)
Net earnings $ 173.6  $ 165.1 
Net earnings per share:
Basic $ 0.49  $ 0.46 
Diluted $ 0.49  $ 0.45 
Average common stock and common equivalent shares outstanding:
Basic 353.6  359.3 
Diluted 356.5  368.4 

See the accompanying Notes to Consolidated Condensed Financial Statements.
5
Table of Contents
FORTIVE CORPORATION AND SUBSIDIARIES
CONSOLIDATED CONDENSED STATEMENTS OF COMPREHENSIVE INCOME (LOSS)
($ in millions)
(unaudited)
 
  Three Months Ended
March 31, 2023 April 1, 2022
Net earnings $ 173.6  $ 165.1 
Other comprehensive income (loss), net of income taxes:
Foreign currency translation adjustments 13.4  (39.4)
Pension adjustments —  0.5 
Total other comprehensive income (loss), net of income taxes 13.4  (38.9)
Comprehensive income $ 187.0  $ 126.2 
See the accompanying Notes to Consolidated Condensed Financial Statements.

6
Table of Contents
FORTIVE CORPORATION AND SUBSIDIARIES
CONSOLIDATED CONDENSED STATEMENTS OF CHANGES IN EQUITY
($ and shares in millions)
(unaudited)
 
Common Stock Additional Paid-In Capital Treasury Shares Retained Earnings Accumulated
Other
Comprehensive
Loss		 Noncontrolling
Interests
Shares Outstanding Amount
Balance, December 31, 2022 352.9  $ 3.6  $ 3,706.3  $ (442.9) $ 6,742.1  $ (325.7) $ 5.2 
Net earnings for the period —  —  —  —  173.6  —  — 
Dividends to common shareholders —  —  —  —  (24.7) —  — 
Other comprehensive income —  —  —  —  —  13.4  — 
Common stock-based award activity 0.8  —  36.3  —  —  —  — 
Shares withheld for taxes (0.2) —  (12.1) —  —  —  — 
Change in noncontrolling interests —  —  —  —  —  —  0.6 
Balance, March 31, 2023 353.5  $ 3.6  $ 3,730.5  $ (442.9) $ 6,891.0  $ (312.3) $ 5.8 

Common Stock Additional Paid-In Capital Treasury Shares Retained Earnings Accumulated
Other
Comprehensive
Loss		 Noncontrolling
Interests
Shares Outstanding Amount
Balance, December 31, 2021 359.1  $ 3.6  $ 3,670.0  $ —  $ 6,023.6  $ (185.0) $ 4.8 
Adoption of ASU 2020-06 —  —  (65.7) —  62.8  —  — 
Balance, January 1, 2022 359.1  3.6  3,604.3  —  6,086.4  (185.0) 4.8 
Net earnings for the period —  —  —  —  165.1  —  — 
Dividends to common shareholders —  —  —  —  (25.1) —  — 
Other comprehensive income (loss) —  —  —  —  —  (38.9) — 
Common stock-based award activity 0.5  —  23.8  —  —  —  — 
Common stock repurchases (1.0) —  —  (63.8) —  —  — 
Shares withheld for taxes (0.2) —  (9.0) —  —  —  — 
Change in noncontrolling interest —  —  —  —  —  —  0.5 
Balance, April 1, 2022 358.4  $ 3.6  $ 3,619.1  $ (63.8) $ 6,226.4  $ (223.9) $ 5.3 

See the accompanying Notes to Consolidated Condensed Financial Statements.
7
Table of Contents
FORTIVE CORPORATION AND SUBSIDIARIES
CONSOLIDATED CONDENSED STATEMENTS OF CASH FLOWS
($ in millions)
(unaudited)
  Three Months Ended
  March 31, 2023 April 1, 2022
Cash flows from operating activities:
Net earnings $ 173.6  $ 165.1 
Noncash items:
Amortization 92.4  96.3 
Depreciation 20.4  21.5 
Stock-based compensation expense 26.7  19.9 
Change in trade accounts receivable, net 21.5  (1.4)
Change in inventories (33.6) (43.2)
Change in trade accounts payable (32.3) 19.2 
Change in prepaid expenses and other assets (16.3) (31.4)
Change in accrued expenses and other liabilities (78.0) (31.2)
Net cash provided by operating activities 174.4  214.8 
Cash flows from investing activities:
Payments for additions to property, plant and equipment (24.8) (18.8)
Cash paid for acquisitions, net of cash received —  0.9 
Net cash used in investing activities (24.8) (17.9)
Cash flows from financing activities:
Net proceeds from (repayments of) commercial paper borrowings (159.3) 930.7 
Payment of 0.875% convertible senior notes due 2022
 —  (1,156.5)
Repurchase of common shares —  (63.8)
Payment of dividends (24.7) (25.1)
All other financing activities (3.1) (17.9)
Net cash used in financing activities (187.1) (332.6)
Effect of exchange rate changes on cash and equivalents 1.1  0.7 
Net change in cash and equivalents (36.4) (135.0)
Beginning balance of cash and equivalents 709.2  819.3 
Ending balance of cash and equivalents $ 672.8  $ 684.3 
See the accompanying Notes to Consolidated Condensed Financial Statements.
8
Table of Contents
FORTIVE CORPORATION AND SUBSIDIARIES
NOTES TO CONSOLIDATED CONDENSED FINANCIAL STATEMENTS
NOTE 1. BUSINESS OVERVIEW
Fortive Corporation (“Fortive,” “the Company,” “we,” “us,” or “our”) is a provider of essential technologies for connected workflow solutions across a range of attractive end-markets. Our strategic segments - Intelligent Operating Solutions, Precision Technologies, and Advanced Healthcare Solutions - include well-known brands with leading positions in their markets. Our businesses design, develop, manufacture, and service professional and engineered products, software, and services, building upon leading brand names, innovative technologies, and significant market positions. Our research and development, manufacturing, sales, distribution, service, and administrative facilities are located in more than 50 countries around the world.
We prepared the unaudited consolidated condensed financial statements included herein in accordance with accounting principles generally accepted in the United States of America (“GAAP”) and the rules and regulations of the U.S. Securities and Exchange Commission (the “SEC”) applicable for interim periods. Certain information and footnote disclosures normally included in financial statements prepared in accordance with GAAP have been omitted pursuant to such rules and regulations; however, we believe the disclosures are adequate to make the information presented not misleading. The unaudited consolidated condensed financial statements included herein should be read in conjunction with the audited annual consolidated financial statements as of and for the year ended December 31, 2022 and the footnotes (“Notes”) thereto included within our 2022 Annual Report on Form 10-K.
In our opinion, the accompanying financial statements contain all adjustments, which consist of only normal, recurring accruals necessary to fairly present our financial position, results of operations, comprehensive income, stockholders’ equity, and cash flows for the periods presented. The results of operations for the three months ended March 31, 2023, are not necessarily indicative of the results for the full year.
Accumulated Other Comprehensive Loss
Foreign currency translation adjustments are generally not adjusted for income taxes as they relate to indefinite investments in non-U.S. subsidiaries. During the second quarter of 2022, our ¥14.4 billion Yen-denominated term loan and our €275 million Euro-denominated term loan were designated as net investment hedges of our investment in applicable foreign operations.
During the three month period ended March 31, 2023, we recognized after-tax foreign currency transaction losses of $1.7 million on the debt that was deferred in the foreign currency translation component of Accumulated other comprehensive income (loss) (“AOCI”) as an offset to the foreign currency translation adjustments on our investments in foreign subsidiaries. Any amounts deferred in AOCI will remain until the hedged investment is sold or substantially liquidated. We recorded no ineffectiveness from our net investment hedges during the three month period ended March 31, 2023.
9
Table of Contents

The changes in AOCI by component are summarized below ($ in millions):
Foreign
currency
translation
adjustments
Pension & post-retirement plan benefit adjustments (a)
Total
For the Three Months Ended March 31, 2023:
Balance, December 31, 2022 $ (301.4) $ (24.3) $ (325.7)
Other comprehensive income (loss) before reclassifications, net of income taxes 13.4  —  13.4 
Amounts reclassified from accumulated other comprehensive income (loss):
Increase (decrease) —  0.1 
(b)
 0.1 
Income tax impact —  (0.1) (0.1)
Amounts reclassified from accumulated other comprehensive income (loss), net of income taxes —  —  — 
Net current period other comprehensive income (loss), net of income taxes 13.4  —  13.4 
Balance, March 31, 2023 $ (288.0) $ (24.3) $ (312.3)
For the Three Months Ended April 1, 2022:
Balance, December 31, 2021 $ (122.7) $ (62.3) $ (185.0)
Other comprehensive income (loss) before reclassifications, net of income taxes (39.4) —  (39.4)
Amounts reclassified from accumulated other comprehensive income (loss):
Increase (decrease) —  0.6 
(b)
 0.6 
Income tax impact —  (0.1) (0.1)
Amounts reclassified from accumulated other comprehensive income (loss), net of income taxes —  0.5  0.5 
Net current period other comprehensive income (loss), net of income taxes (39.4) 0.5  (38.9)
Balance, April 1, 2022 $ (162.1) $ (61.8) $ (223.9)
(a) Includes balances relating to defined benefit plans, supplemental executive retirement plans, and other postretirement employee benefit plans.
(b) This component of AOCI is included in the computation of net periodic pension cost (refer to Note 12 in our most recently filed Form 10-K for additional details).
Allowances for Doubtful Accounts
All trade accounts and unbilled receivables are reported in the Consolidated Condensed Balance Sheet adjusted for any write-offs and net of allowances for credit losses. The allowances for credit losses represent management’s best estimate of the credit losses expected from our unbilled and trade accounts receivable portfolios over the life of the underlying assets. Additions to the allowances are charged to current period earnings, amounts determined to be uncollectible are charged directly against the allowances, while amounts recovered on previously written-off accounts increase the allowances. During the three month period ending March 31, 2023, the activity was immaterial.
Restructuring
We initiated a discrete plan in the first quarter of 2023 focused on improvements in our operational efficiency, which is expected to be completed by December 31, 2023. The nature of these activities were broadly consistent throughout our segments and consist of targeted workforce reductions and facility consolidations or closures in response to overall macroeconomic and other external conditions. We incurred these costs to position ourselves to provide superior products and services to customers in a cost-efficient manner, while taking into consideration the impact of broad economic uncertainties. The total restructuring charges we expect to recognize under this discrete plan are approximately $25 to $30 million, with charges of $17.6 million incurred in the first quarter, which primarily related to employee severance. These charges are included in Cost of Sales and Selling, general, and administrative expenses in the Consolidated Condensed Statement of
10
Table of Contents
Earnings. Accrued restructuring costs were $13.4 million as of March 31, 2023 and were included within Accrued expenses and other current liabilities in the Consolidated Condensed Balance Sheets.
Convertible Senior Notes
On February 22, 2019, we issued $1.4 billion in aggregate principal amount of our 0.875% Convertible Senior Notes due 2022 (“Convertible Notes”), including $187.5 million in aggregate principal amount resulting from an exercise in full of an over-allotment option. The Convertible Notes were issued in a private placement to certain initial purchasers for resale to qualified institutional buyers pursuant to Rule 144A under the Securities Act. Upon conversion of the Convertible Notes, holders were entitled to receive cash, shares of our common stock, or a combination thereof, at our election. Upon adopting Accounting Standards Update No. 2020-06, Debt—Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging—Contracts in Entity’s Own Equity (Subtopic 815-40): Accounting for Convertible Instruments and Contracts in an Entity’s Own Equity (“ASU 2020-06”), on January 1, 2022, we accounted for the Convertible Notes under the if-converted method in our calculation of diluted EPS, as required under the new guidance.
On February 15, 2022, the maturity date of the Convertible Notes, Fortive repaid, in cash, $1.2 billion in outstanding principal and accrued interest thereon.
Recently Issued Accounting Standard
The Financial Accounting Standards Board (“FASB”) establishes changes to accounting principles under GAAP in the form of accounting standards updates (“ASUs”) to the Accounting Standards Codification (“ASC”). We consider the applicability and impact of all ASUs. Any recently issued ASUs were assessed and determined to be either not applicable or are expected to have an immaterial impact on the Company’s result of operations, financials position or cash flows.
NOTE 2. GOODWILL
The following is a roll forward of our carrying value of goodwill by segment ($ in millions):
Intelligent Operating Solutions Precision Technologies Advanced Healthcare Solutions Total Goodwill
Balance, December 31, 2022 $ 4,074.4  $ 1,810.2  $ 3,163.9  $ 9,048.5 
Foreign currency translation and other 6.6  1.4  0.6  8.6 
Balance, March 31, 2023 $ 4,081.0  $ 1,811.6  $ 3,164.5  $ 9,057.1 
NOTE 3. FAIR VALUE MEASUREMENTS
Accounting standards define fair value based on an exit price model, establish a framework for measuring fair value where our assets and liabilities are required to be carried at fair value, and provide for certain disclosures related to the valuation methods used within a valuation hierarchy as established within the accounting standards. This hierarchy prioritizes the inputs into three broad levels as follows:
•Level 1 inputs are quoted prices (unadjusted) for identical assets or liabilities in active markets.
•Level 2 inputs are quoted prices for similar assets and liabilities in active markets, quoted prices for identical or similar assets in markets that are not active, or other observable characteristics for the asset or liability, including interest rates, yield curves and credit risks, or inputs that are derived principally from, or corroborated by, observable market data through correlation.
•Level 3 inputs are unobservable inputs based on our assumptions. The classification of a financial asset or liability within the hierarchy is determined based on the lowest level input that is significant to the fair value measurement in its entirety.
11
Table of Contents
Below is a summary of financial liabilities that are measured at fair value on a recurring basis ($ in millions):
Quoted Prices
in Active
Market
(Level 1)		 Significant Other
Observable Inputs
(Level 2)		 Significant
Unobservable
Inputs
(Level 3)		 Total
March 31, 2023
Deferred compensation liabilities $ —  $ 35.4  $ —  $ 35.4 
December 31, 2022
Deferred compensation liabilities —  31.5  —  31.5 
Certain management employees participate in our nonqualified deferred compensation programs that permit such employees to defer a portion of their compensation, on a pretax basis, until after their termination of employment. All amounts deferred under such plans are unfunded, unsecured obligations and are included in Other long-term liabilities in the accompanying Consolidated Condensed Balance Sheets. Participants may choose among alternative earnings rates for the amounts they defer, which are primarily based on investment options within our defined contribution plans for the benefit of U.S. employees (except that the earnings rates for amounts contributed unilaterally by the Company are entirely based on changes in the value of Fortive common stock). Changes in the deferred compensation liability under these programs are recognized based on changes in the fair value of the participants’ accounts and are recorded within selling, general and administrative in the Consolidated Condensed Statements of Earnings.
Non-recurring Fair Value Measurements
Certain non-financial assets, primarily property, plant, and equipment, goodwill, and intangible assets, are not required to be measured at fair value on a recurring basis and are reported at their carrying value. However, these assets are required to be assessed for impairment whenever events or circumstances indicate that their carrying value may not be fully recoverable, and at least annually for goodwill and indefinite-lived intangible assets.
We evaluated events or circumstances that may indicate the carrying value of our non-financial assets may not be fully recoverable during the three month period ended March 31, 2023, and recorded no impairments.
Fair Value of Financial Instruments
The carrying amount and fair value of financial instruments are as follows ($ in millions):
March 31, 2023 December 31, 2022
Carrying Amount Fair Value Carrying Amount Fair Value
Current portion of long-term debt $ 999.8  $ 1,000.0  $ 999.7  $ 1,000.0 
Long-term debt, net of current maturities 2,094.6  1,952.7  2,251.6  2,078.1 
As of March 31, 2023 and December 31, 2022, the current portion of long-term debt and long-term debt, net of current maturities were categorized as Level 1.
The fair values of long-term borrowings were based on quoted market prices. The difference between the fair value and the carrying amounts of long-term borrowings may be attributable to changes in market interest rates and/or our credit ratings subsequent to the borrowing. The fair value of cash and cash equivalents, trade accounts receivable, net, trade accounts payable, and commercial paper approximates their carrying value due to the short-term maturities of these instruments.
12
Table of Contents
NOTE 4. FINANCING
The components of our debt were as follows ($ in millions):
March 31, 2023 December 31, 2022
U.S. dollar-denominated commercial paper $ 245.0  $ 405.0 
Delayed-Draw Term Loan due 2023 1,000.0  1,000.0 
Euro Term Loan due 2025 298.1  294.4 
Yen Term Loan due 2025 108.4  109.8 
3.15% senior unsecured notes due 2026
 900.0  900.0 
4.30% senior unsecured notes due 2046
 550.0  550.0 
Long-term debt, principal amounts 3,101.5  3,259.2 
Less: aggregate unamortized debt discounts, premiums, and issuance costs 7.1  7.9 
Long-term debt, carrying value 3,094.4  3,251.3 
Less: current portion of long-term debt 999.8  999.7 
Long-term debt, net of current maturities $ 2,094.6  $ 2,251.6 
Refer to Note 11 of our 2022 Annual Report on Form 10-K for further details of our debt financing.
Other Liquidity Sources
We generally satisfy any short-term liquidity needs that are not met through operating cash flows and available cash primarily through issuances of commercial paper under our U.S. dollar and Euro-denominated commercial paper programs (“Commercial Paper Programs”). Under these programs, we may issue unsecured promissory notes with maturities not exceeding 397 and 183 days, respectively.
Interest expense on commercial paper is paid at maturity and is generally based on our credit ratings at the time of issuance and prevailing short-term interest rates.

The details of our outstanding Commercial Paper Programs as of March 31, 2023 were as follows ($ in millions):
Carrying value Annual effective rate Weighted average maturity (in days)
U.S. dollar-denominated commercial paper $ 244.9  4.98  % 30
Credit support for the Commercial Paper Programs is provided by a five-year $2.0 billion senior unsecured revolving credit facility that expires on October 18, 2027 (the “Revolving Credit Facility”) which, to the extent not otherwise providing credit support for our commercial paper programs, can also be used for working capital and other general corporate purposes. As of March 31, 2023, no borrowings were outstanding under the Revolving Credit Facility.
We classified our borrowings outstanding under the Commercial Paper Programs as Long-term debt in the accompanying Consolidated Condensed Balance Sheets as we had the intent and ability, as supported by availability under the Revolving Credit Facility, to refinance these borrowings for at least one year from the balance sheet date.
NOTE 5. SALES
We derive revenue primarily from the sale of products, including software, and services. Revenue is recognized when control of promised products or services is transferred to customers in an amount that reflects the consideration we expect to be entitled to in exchange for those products, software, or services. 
Product sales include revenue from the sale of products and equipment, which includes our software and SaaS product offerings and equipment rentals. Service sales include revenues from extended warranties, post-contract customer support (“PCS”), maintenance contracts or services, contract labor to perform ongoing service at a customer location, services related to previously sold products, and software implementation services.
Contract Assets — In certain circumstances, we record contract assets which include unbilled amounts typically resulting from sales under contracts when revenue recognized exceeds the amount billed to the customer, and right to payment is not only subject to the passage of time. Contract assets were $96 million as of March 31, 2023 and $82 million as of December 31, 2022. Contract assets are recorded in Prepaid expenses and other current assets in our Consolidated Condensed Balance Sheets.
13
Table of Contents
Contract Costs — We incur and capitalize incremental costs to obtain certain contracts, typically sales-related commissions where the amortization period is greater than one year and costs associated with assets used by our customers in certain service arrangements. As of March 31, 2023 and December 31, 2022, we had $44 million and $42 million, respectively, in net revenue-related contract costs primarily related to certain software contracts. Revenue-related contract costs are recorded in the Prepaid expenses and other current assets and Other assets line items in our Consolidated Condensed Balance Sheets. These assets have estimated useful lives between three and five years.
Contract Liabilities — Our contract liabilities consist of deferred revenue generally related to subscription-based software contracts, PCS and extended warranty sales, where we generally receive up-front payment and recognize revenue over the service or support term. We classify deferred revenue as current or noncurrent based on the timing of when we expect to recognize revenue. The current portion of deferred revenue is included in Accrued expenses and other current liabilities and the noncurrent portion of deferred revenue is included in Other long-term liabilities in our Consolidated Condensed Balance Sheets.
Our contract liabilities consisted of the following ($ in millions):
March 31, 2023 December 31, 2022
Deferred revenue - current $ 497.2  $ 509.6 
Deferred revenue - noncurrent 38.9  38.0 
Total contract liabilities $ 536.1  $ 547.6 
During the three month period ended March 31, 2023, we recognized revenue related to our contract liabilities at December 31, 2022 of $175 million. The change in our contract liabilities from December 31, 2022 to March 31, 2023 was primarily due to the timing of billings and recognition as revenue of subscription-based software contracts, PCS and extended warranty services.
Remaining Performance Obligations — Our remaining performance obligations represent the transaction price of firm, non-cancelable orders and the average contract value for software contracts, for which work has not been performed. We have excluded performance obligations with an original expected duration of one year or less from the amounts below.
The aggregate remaining performance obligations attributable to each of our segments is as follows ($ in millions):
March 31, 2023
Intelligent Operating Solutions $ 576.2 
Precision Technologies 55.9 
Advanced Healthcare Solutions 67.0 
Total remaining performance obligations $ 699.1 
The majority of remaining performance obligations are related to service and support contracts, which we expect to fulfill approximately 80 percent within the next two years, approximately 95 percent within the next three years, and substantially all within four years.
14
Table of Contents
Disaggregation of Revenue
We disaggregate revenue from contracts with customers by sales of products and software and services, geographic location, and end market for each of our segments, as we believe it best depicts how the nature, amount, timing and uncertainty of our revenue and cash flows are affected by economic factors.
Disaggregation of revenue for the three month periods ended March 31, 2023 is presented as follows ($ in millions):
Total Intelligent Operating Solutions Precision Technologies Advanced Healthcare Solutions    
Sales:
Sales of products and software $ 1,236.6  $ 537.4  $ 460.3  $ 238.9 
Sales of services 224.1  94.7  55.2  74.2 
Total $ 1,460.7  $ 632.1  $ 515.5  $ 313.1 
Geographic:
United States $ 771.5  $ 340.1  $ 251.3  $ 180.1 
China 181.4  64.9  92.2  24.3 
All other (each country individually less than 5% of total sales) 507.8  227.1  172.0  108.7 
Total $ 1,460.7  $ 632.1  $ 515.5  $ 313.1 
End markets:(a)
Direct sales:
  Healthcare $ 339.4  $ 10.9  $ 34.5  $ 294.0 
  Industrial & Manufacturing 353.2  228.3  118.2  6.7 
  Utilities & Power 98.9  47.3  51.6  — 
  Government 111.1  61.8  40.9  8.4 
  Communications, Electronics & Semiconductor 105.9  25.6  79.6  0.7 
  Aerospace & Defense 67.6  0.1  67.5  — 
  Oil & Gas 70.3  65.9  4.4  — 
  Retail & Consumer 82.9  62.3  20.6  — 
  Other 170.1  95.0  75.1  — 
     Total direct sales 1,399.4  597.2  492.4  309.8 
Distributors 61.3  34.9  23.1  3.3 
Total $ 1,460.7  $ 632.1  $ 515.5  $ 313.1 
(a) Direct sales by end market include sales made through third-party distributors where we have visibility into the end customer.


15
Table of Contents
Disaggregation of revenue for the three month periods ended April 1, 2022 is presented as follows ($ in millions):
Total Intelligent Operating Solutions Precision Technologies Advanced Healthcare Solutions    
Sales:
Sales of products and software $ 1,152.7  $ 500.5  $ 410.6  $ 241.6 
Sales of services 223.8  87.1  51.8  84.9 
Total $ 1,376.5  $ 587.6  $ 462.4  $ 326.5 
Geographic:
United States $ 739.9  $ 321.9  $ 234.0  $ 184.0 
China 145.4  47.9  69.3  28.2 
All other (each country individually less than 5% of total sales) 491.2  217.8  159.1  114.3 
Total $ 1,376.5  $ 587.6  $ 462.4  $ 326.5 
End markets:(a)
Direct sales:
  Healthcare $ 353.3  $ 10.3  $ 37.1  $ 305.9 
  Industrial & Manufacturing 321.9  211.1  103.7  7.1 
  Utilities & Power 86.3  43.0  43.3  — 
  Government 105.7  51.6  44.7  9.4 
  Communications, Electronics & Semiconductor 87.8  23.8  63.4  0.6 
  Aerospace & Defense 55.4  0.1  55.3  — 
  Oil & Gas 64.8  62.3  2.5  — 
  Retail & Consumer 81.2  63.7  17.5  — 
  Other 153.9  87.5  66.3  0.1 
     Total direct sales 1,310.3  553.4  433.8  323.1 
Distributors 66.2  34.2  28.6  3.4 
Total $ 1,376.5  $ 587.6  $ 462.4  $ 326.5 
(a) Direct sales by end market include sales made through third-party distributors where we have visibility into the end customer.
NOTE 6. INCOME TAXES
Our effective tax rates for the three month period ended March 31, 2023 was 15.7%, as compared to 13.5%, for the three month period ended April 1, 2022. The year-over-year increase in the effective tax rate for the three month period ended March 31, 2023 as compared to the three month period ended April 1, 2022 was primarily due to uncertain tax position reserves released during the three month period ending April 1, 2022.
Our effective tax rates for the three month periods ended March 31, 2023 and April 1, 2022, differ from the U.S. federal statutory rate of 21% due primarily to the impact of credits and deductions provided by law and changes in our uncertain tax position reserves.
On August 16, 2022, the U.S. enacted the Inflation Reduction Act of 2022, which, among other provisions, implements a 15% corporate alternative minimum tax on book income on corporations whose average annual adjusted financial statement income during the most recently-completed three-year period exceeds $1.0 billion. This provision is effective for tax years beginning after December 31, 2022. Based upon our analysis of the Inflation Reduction Act of 2022 and subsequently released guidance, we believe that the corporate alternative minimum tax will not have a material impact on our financial statements in 2023.
16
Table of Contents
NOTE 7. STOCK-BASED COMPENSATION
The 2016 Stock Incentive Plan (the “Stock Plan”), provides for the grant of stock appreciation rights, restricted stock units, and performance stock units (collectively, “Stock Awards”), stock options, or any other stock-based award. As of March 31, 2023, approximately 14 million shares of our common stock were available for subsequent issuance under the Stock Plan. For a full description of our Stock Plan refer to Note 17 of our 2022 Annual Report on Form 10-K.
Stock-based Compensation Expense
Stock-based compensation has been recognized as a component of Selling, general and administrative expenses in the Consolidated Condensed Statements of Earnings based on the portion of the awards that are ultimately expected to vest.
The following summarizes the components of our stock-based compensation expense under the Stock Plan ($ in millions):
  Three Months Ended
  March 31, 2023 April 1, 2022
Stock Awards:
Pretax compensation expense $ 18.1  $ 12.7 
Income tax benefit (2.6) (1.7)
Stock Award expense, net of income taxes 15.5  11.0 
Stock options:
Pretax compensation expense 8.6  7.2 
Income tax benefit (1.2) (1.0)
Stock option expense, net of income taxes 7.4  6.2 
Total stock-based compensation:
Pretax compensation expense 26.7  19.9 
Income tax benefit (3.8) (2.7)
Total stock-based compensation expense, net of income taxes $ 22.9  $ 17.2 
The following summarizes the unrecognized compensation cost for the Stock Plan awards as of March 31, 2023. This compensation cost is expected to be recognized over a weighted average period of approximately two years, representing the remaining service period related to the awards. Future compensation amounts will be adjusted for any changes in estimated forfeitures ($ in millions):
Stock Awards $ 142.6 
Stock options 64.2 
Total unrecognized compensation cost $ 206.8 


17
Table of Contents
NOTE 8. COMMITMENTS AND CONTINGENCIES
For a description of our litigation and contingencies and additional information about our leases, refer to Note 16 and Note 10, respectively, in our 2022 Annual Report on Form 10-K.
Warranty
We generally accrue estimated warranty costs at the time of sale. In general, manufactured products are warranted against defects in material and workmanship when properly used for their intended purpose, installed correctly, and appropriately maintained. Warranty period terms depend on the nature of the product and range from 90 days up to the life of the product. The amount of the accrued warranty liability is determined based on historical information such as past experience, product failure rates or number of units repaired, estimated cost of material and labor, and, in certain instances, estimated property damage. The accrued warranty liability is reviewed on a quarterly basis and may be adjusted as additional information regarding expected warranty costs becomes known. During the three month period ending March 31, 2023, warranty related activity was immaterial.
Leases
Operating lease cost for the three month periods ended March 31, 2023 and April 1, 2022 was $12 million and $15 million, respectively. During the three month periods ended March 31, 2023 and April 1, 2022, cash paid for operating leases included in operating cash flows was $12 million and $14 million, respectively. Right-of-use (“ROU”) assets obtained in exchange for operating lease obligations were $4 million and $2 million during the three month periods ended March 31, 2023 and April 1, 2022, respectively. Operating lease ROU assets were $155 million and $162 million as of March 31, 2023 and December 31, 2022, respectively. Operating lease liabilities were $162 million and $169 million as of March 31, 2023 and December 31, 2022, respectively. Operating lease ROU assets and operating lease liabilities are reported on the Consolidated Condensed Balance Sheets within Other assets, Accrued expenses and Other current liabilities and Other long-term liabilities, respectively.
NOTE 9. NET EARNINGS PER SHARE
Basic net EPS is calculated by dividing net earnings attributable to common stockholders by the weighted average number of shares of common stock outstanding for the applicable period. Diluted EPS is similarly calculated, except that the calculation includes the dilutive effect of the assumed conversion of 0.875% Convertible Notes and associated issuance of shares under the if-converted method, while outstanding in 2022, and the assumed issuance of shares under stock-based compensation plans under the treasury stock method, except where the inclusion of such shares would have an anti-dilutive impact. Anti-dilutive options excluded from the diluted EPS calculation for the three month periods ended March 31, 2023 and April 1, 2022 were 2.9 million and 3.1 million, respectively.
18
Table of Contents

Information related to the calculation of net earnings per share of common stock is summarized as follows ($ and shares in millions, except per share amounts):
Three Months Ended
  March 31, 2023 April 1, 2022
Numerator
Net earnings $ 173.6  $ 165.1 
Convertible note interest add-back (if converted method) —  1.8 
Diluted Net Earnings $ 173.6  $ 166.9 
Denominator
Weighted average common shares outstanding used in basic earnings per share 353.6  359.3 
Incremental common shares from:
Assumed exercise of dilutive options and vesting of dilutive Stock Awards 2.9  2.7